arrow
A

Amit Bahl

University Hospitals Bristol and Weston NHS Foundation Trust
H指数:39
被引数:6,663

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer – a multicentre evaluation

前列腺癌中[18F]PSMA-1007 PET/CT显像中PSMA-RADS版本2.0与骨摄取转移概率(BUMP)评分对特征性骨摄取的比较分析——一项多中心评估

2026-09-010
OAAI
Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

回复Parth Aphale、Shashank Dokania、Himanshu Shekhar致编辑的信函:关于Bahl A、Chilelli A、Faria R等人撰写的“乙酸盐比卡鲁他胺与恩杂鲁胺在转移性去势抵抗性前列腺癌患者中主要心血管事件关联性的比较:EVADE研究的事后分析”一文。World J Urol 43:465。https://doi.org/10.1007/s00345-025-05841-9

2025-11-270
OAAI
Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study

醋酸阿比特龙与恩扎卢amide在转移性去势抵抗性前列腺癌患者中主要心血管事件关联性的比较:EVADE研究的事后分析

2025-08-010
OAAI
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings

荟萃分析评估真实环境中恩扎鲁他胺和醋酸阿比曲酮一线治疗转移性去势抵抗性前列腺癌的疗效比较

2025-02-100
OAAI
Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?

真实世界数据对转移性肾癌治疗模式的挑战:是时候区分IMDC中危/高危组了吗?

2024-09-010
PRE
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer
BREAST
IF7.9
2022-12-014
OAAI
Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer

177Lu-PSMA治疗的资格取决于伴侣诊断示踪剂的选择: 转移性去势抵抗性前列腺癌中68Ga-PSMA-11和99mTc-MIP-1404的比较

2022-10-277
OAAI
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

英国和瑞士转移性前列腺癌患者的前列腺放射治疗: STAMPEDE随机对照试验的长期结果

2022-06-0751
OAAI
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)
2021-09-016
OAAI